GeneHealth - Your precision medicine

Smith-lemli-opitz Syndrome

Disease Details

Family Health Simplified

Buy Membership

Description: Smith-Lemli-Opitz syndrome is a genetic disorder characterized by developmental abnormalities, intellectual disability, and distinctive facial features, caused by a defect in cholesterol biosynthesis.
Type: Smith-Lemli-Opitz syndrome (SLOS) is a congenital disorder. It is transmitted in an autosomal recessive manner.
Signs And Symptoms: SLOS can present itself differently in different cases, depending on the severity of the mutation and other factors. Originally, SLOS patients were classified into two categories (classic and severe) based on physical and mental characteristics, alongside other clinical features. Since the discovery of the specific biochemical defect responsible for SLOS, patients are given a severity score based on their levels of cerebral, ocular, oral, and genital defects. It is then used to classify patients as having mild, classical, or severe SLOS.
Prognosis: Smith-Lemli-Opitz syndrome (SLOS) prognosis is quite variable and depends on the severity of symptoms. While individuals with milder forms may survive into adulthood with some intellectual disability and physical anomalies, severe cases can result in significant physical and intellectual challenges and reduced life expectancy. Early intervention and supportive care can help manage symptoms and improve quality of life.
Onset: Smith-Lemli-Opitz syndrome (SLOS) typically presents its onset during the prenatal period or at birth. The condition is congenital, meaning it is present from birth.
Prevalence: Smith-Lemli-Opitz Syndrome (SLOS) has a prevalence of approximately 1 in 20,000 to 1 in 60,000 live births.
Epidemiology: Smith-Lemli-Opitz syndrome (SLOS) is a rare genetic disorder that primarily affects cholesterol metabolism.

Epidemiology:
- SLOS is estimated to occur in about 1 in 20,000 to 1 in 60,000 live births.
- It is more common in populations of European descent and less common in other populations.
- The syndrome results from mutations in the DHCR7 gene, which are inherited in an autosomal recessive manner.

Prevalence rates may vary by region and ethnic background.
Intractability: Smith-Lemli-Opitz syndrome (SLOS) is a genetic disorder that is currently considered intractable, meaning it has no cure. The condition is caused by mutations in the DHCR7 gene leading to impaired cholesterol synthesis. Management is primarily supportive and focuses on alleviating symptoms and improving quality of life through dietary supplementation with cholesterol and other therapeutic measures.
Disease Severity: The severity of Smith-Lemli-Opitz syndrome (SLOS) can vary widely among affected individuals. Some people may have mild symptoms, including minor physical abnormalities and developmental delays, while others can experience severe intellectual disability, major congenital malformations, and life-threatening health problems. Symptoms and severity depend on the level of deficiency in cholesterol synthesis and other contributing factors.
Healthcare Professionals: Disease Ontology ID - DOID:14692
Pathophysiology: Smith-Lemli-Opitz Syndrome (SLOS) is a genetic disorder caused by a deficiency in the enzyme 7-dehydrocholesterol reductase (DHCR7). This enzyme is crucial for the final step in cholesterol synthesis, converting 7-dehydrocholesterol (7-DHC) to cholesterol. Due to the enzyme deficiency, individuals with SLOS have low cholesterol levels and elevated levels of 7-DHC.

Cholesterol is vital for numerous biological processes, including the formation of cell membranes, myelin production (which insulates nerve cells), and the synthesis of steroid hormones and bile acids. Insufficient cholesterol and the accumulation of 7-DHC disrupt these processes, leading to a spectrum of clinical manifestations including intellectual disability, behavioral problems, growth delays, and multiple congenital anomalies affecting various organ systems such as the brain, heart, and limbs.
Carrier Status: For Smith-Lemli-Opitz syndrome (SLOS):

Carrier Status: Smith-Lemli-Opitz syndrome is an autosomal recessive genetic disorder, meaning that an individual must inherit two copies of the mutated gene (one from each parent) to express the condition. Carriers, who have one mutated gene and one normal gene, typically do not show symptoms of the syndrome but can pass the mutated gene to their offspring.

Nan: If seeking information on nanotechnology or related aspects in relation to SLOS, it is not a directly relevant connection. Please provide additional context for clarification if needed.
Mechanism: Smith-Lemli-Opitz syndrome (SLOS) is a genetic disorder caused by mutations in the DHCR7 gene, which encodes the enzyme 7-dehydrocholesterol reductase. This enzyme is crucial for the final step in the biosynthesis of cholesterol.

### Mechanism:
The DHCR7 gene mutations lead to a deficiency or malfunction of the 7-dehydrocholesterol reductase enzyme. As a result, there is an accumulation of 7-dehydrocholesterol and a deficiency of cholesterol in the body.

### Molecular Mechanisms:
1. **Loss of Function of DHCR7 Enzyme**: Mutations in DHCR7 can result in either a complete loss or reduced function of the enzyme, impairing the conversion of 7-dehydrocholesterol to cholesterol.

2. **Cholesterol Deficiency**: Cholesterol is vital for cell membrane integrity, synthesis of steroid hormones, and development of the central nervous system. Its deficiency disrupts these processes, contributing to the clinical features of SLOS.

3. **Accumulation of 7-Dehydrocholesterol**: The buildup of 7-dehydrocholesterol can be toxic, further contributing to developmental abnormalities and other symptoms observed in SLOS.

Understanding these mechanisms is crucial for diagnosing and developing potential therapies for Smith-Lemli-Opitz syndrome.
Treatment: Management of individuals with SLOS is complex and often requires a team of specialists. Some of the congenital malformations (cleft palate) can be corrected with surgery. Other treatments have yet to be proven successful in randomized studies, however anecdotally they appear to cause improvements.
Compassionate Use Treatment: Smith-Lemli-Opitz Syndrome (SLOS) is a genetic disorder that affects cholesterol metabolism. While there is no definitive cure, some experimental and compassionate use treatments are being explored:

1. **Cholesterol Supplementation**: Since individuals with SLOS have low cholesterol levels, dietary cholesterol supplements are often given to help normalize cholesterol levels and improve clinical symptoms.

2. **Simvastatin**: Statins, specifically simvastatin, are being investigated as they may help reduce the toxic intermediate metabolites that accumulate in SLOS. This is considered an off-label use.

3. **Coenzyme Q10 and Antioxidants**: Some studies suggest that antioxidants like Coenzyme Q10 might be beneficial in reducing oxidative stress in SLOS patients.

4. **Bile Acid Supplementation**: Bile acids are sometimes supplemented to improve cholesterol metabolism and address related symptoms.

It is essential for these treatments to be monitored by healthcare professionals with experience in managing SLOS. Always consult a specialist for the most appropriate and personalized treatment options.
Lifestyle Recommendations: For individuals with Smith-Lemli-Opitz syndrome (SLOS), lifestyle recommendations focus on improving quality of life and managing symptoms. These may include:

1. **Dietary Management**: A diet high in cholesterol can be beneficial, as individuals with SLOS have low cholesterol levels. Cholesterol supplements might also be recommended.

2. **Regular Medical Check-ups**: Frequent visits to healthcare providers, including specialists like geneticists, gastroenterologists, and cardiologists, are important for ongoing care and monitoring.

3. **Developmental Therapies**: Early intervention with physical, occupational, and speech therapy can help address developmental delays and physical disabilities.

4. **Routine Monitoring**: Regular monitoring of growth and developmental milestones, nutritional status, and cholesterol levels to assess overall health and adjust care plans as needed.

5. **Behavioral Support**: Behavioral therapies and strategies can help manage difficulties such as hyperactivity, aggression, or autism spectrum disorder traits, which may be present in some individuals with SLOS.

6. **Educational Support**: Tailored educational plans and special education services can provide the necessary support for learning and cognitive development.

7. **Genetic Counseling**: For families, genetic counseling can be helpful for understanding the condition, informing future family planning, and accessing support resources.

8. **Physical Activities**: Encouraging safe, supervised physical activities that suit individual capabilities can contribute to overall well-being and development.

Living with SLOS requires a comprehensive, multidisciplinary approach to address the various physical, developmental, and behavioral challenges associated with the condition.
Medication: There is no specific medication to cure Smith-Lemli-Opitz syndrome (SLOS), a genetic disorder affecting cholesterol metabolism. However, management may involve dietary cholesterol supplementation and supportive therapies to address symptoms and complications. Patients with SLOS often receive multidisciplinary care, including developmental, nutritional, and medical support tailored to their specific needs.
Repurposable Drugs: Smith-Lemli-Opitz Syndrome (SLOS) is a genetic disorder caused by a deficiency in the enzyme 7-dehydrocholesterol reductase. This enzyme is crucial for cholesterol synthesis. Research into repurposable drugs is ongoing, with some potential candidates including:

1. Statins (e.g., simvastatin) - Though primarily used to lower cholesterol in hypercholesterolemia, statins may help in SLOS by reducing the toxic accumulation of 7-dehydrocholesterol and partially restoring cholesterol levels.
2. Cholesterol Supplementation - While not a drug, administering dietary cholesterol can help manage some of the biochemical abnormalities in SLOS patients.

These interventions aim to ameliorate the metabolic dysfunctions associated with the syndrome. Further clinical trials and studies are required to establish their efficacy and safety specifically for SLOS patients.
Metabolites: Smith-Lemli-Opitz syndrome (SLOS) involves abnormal cholesterol metabolism. Key metabolites include significantly reduced levels of cholesterol and elevated levels of its precursor, 7-dehydrocholesterol (7-DHC). These metabolic abnormalities are due to a deficiency of the enzyme 7-dehydrocholesterol reductase, which is crucial in the final step of cholesterol synthesis.
Nutraceuticals: Smith-Lemli-Opitz syndrome (SLOS) is a genetic disorder caused by a deficiency in the enzyme 7-dehydrocholesterol reductase, leading to impaired cholesterol synthesis. Nutraceuticals, such as cholesterol supplementation, are often utilized in managing this condition. Oral cholesterol supplements can help improve growth, behavioral symptoms, and biochemical abnormalities associated with SLOS. However, the effectiveness can vary among individuals, and ongoing clinical monitoring is necessary to optimize therapy.
Peptides: Smith-Lemli-Opitz Syndrome (SLOS) primarily affects cholesterol metabolism due to a deficiency in the enzyme 7-dehydrocholesterol reductase. Peptides are not the primary focus in the context of SLOS, as the disease is more related to cholesterol biosynthesis rather than peptide pathways. There is no established link between the use of nanotechnology (nan) and the treatment or diagnosis of SLOS as of the most recent data. Research continues in various fields, but peptides and nanotechnology have not been highlighted as significant in this particular syndrome.